ClinicalTrials.gg
CompletedNCT01518036Updated Feb 28, 2017

Use of Somatropin in Turner Syndrome

A Phase 3 interventional study of somatropin and somatropin in Genetic Disorder and Turner Syndrome, sponsored by Novo Nordisk A/S. Completed at 1 site in United Kingdom. Open to female participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-02-28.

Primary conditionTurner SyndromeRegistry: Genetic Diseases, InbornReclassifiedWhy we changed it
Registry
Genetic Diseases, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Turner Syndrome
Why
  1. The study's listed conditions name Turner Syndrome, a narrower term within Genetic Diseases, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 24 years 4 months after the study started (first participant enrolled Sep 1987, registered Jan 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.

Enrollment
11th of 14
57 · median 108
Started
1987
with 1 other
Phase 3
6 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
4 of 14
Novo Nordisk A/S

Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 11th largest by enrollment, is one of 2 that started in 1987, is one of 6 in phase 3, and was the 10th registered.

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

Browse Turner Syndrome studies →

Open to participants now

None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.

This study: 2 Years to 11 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing Human Growth Hormone in Turner Syndrome as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.

03

Conditions studied

  • Genetic Disorder
  • Turner Syndrome

Browse trials for

04

In context

Turner Syndrome Reclassified

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

This study's enrollment of 57 is below the median of 67 across 52 interventional studies indexed under Turner Syndrome.

Browse Turner Syndrome studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Turner Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Turner Syndrome
  • Not previously treated with growth hormone or androgen
  • Well-documented height over the previous 12 months
  • of parents (and child if appropriate)

Exclusion criteria

Exclusion Criteria:

  • Growth hormone (GH) deficiency based on a GH stimulation test
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Low dose

    Drug: somatropin

  • Experimental
    High dose

    Drug: somatropin

Interventions

  • 2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

  • 4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

07

What researchers measure

Primary outcomes

  1. Final height in cm

Secondary outcomes

  1. Ratio between change in bone age and change in chronological age

  2. Age at onset of puberty

  3. Adverse events

08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Crawley, RH11 9RT, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 1987 to primary completion in Apr 2004, 198 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2012
First posted
Jan 25, 2012
StartActual
Sep 14, 1987
Primary completionActual
Apr 11, 2004
CompletionActual
Apr 11, 2004
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01518036
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 25, 2012
Start date
Sep 14, 1987
Primary completion
Apr 11, 2004
Completion
Apr 11, 2004
Last update
Feb 28, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion